Explore Geron's Fair Values from the Community and select yours

Geron (NASDAQ:GERN) Second Quarter 2025 Results

Key Financial Results

• Revenue: US$49.0m (up by US$48.2m from 2Q 2024).
• Net loss: US$16.4m (loss narrowed by 76% from 2Q 2024).
• US$0.025 loss per share (improved from US$0.10 loss in 2Q 2024).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Geron Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 3.7%. Earnings per share (EPS) also surpassed analyst estimates by 31%.

Looking ahead, revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are up 5.8% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of Geron's balance sheet and an in-depth analysis of the company's financial position.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.